In a vote, 17 members on the Cellular, Tissue and Gene Therapies Advisory Committee said Brainstorm’s NurOwn did not show efficacy in treating mild to moderate amyotrophic lateral sclerosis. One voted yes, and another abstained.
The company’s study of 200 patients failed to find that NurOwn improved patient mobility, extended life or slowed the disease that affects about 31,000 people in the U.S., according to the CDC. Despite the lacking efficacy data, the FDA organized the committee meeting after receiving a petition with about 30,000 signatures from ALS patients and advocates.
In the past year, the FDA has approved two ALS drugs, Amylyx Pharmaceuticals’ Relyvrio and Biogen’s Qalsody, after about 20 years without a new ALS drug, according to CBS News.
The FDA does not have to follow the committee’s vote, but the agency usually does. The final decision is expected by Dec. 8.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
